New England Peptide Secures New Equity Financing to Expand Global Peptide Synthesis Capabilities

VCBeat (WeChat ID: vcbeat) learned from foreign media that on October 7, 2019, New England Peptide, a supplier of high-quality custom peptides and antibodies for the global life sciences market, announced the completion of a new round of equity financing led by Ampersand Capital Partners. The financial terms of the transaction were not disclosed.

New England Peptide, founded by Sam and Jennifer Massoni in 1998 and headquartered in Massachusetts, USA, has grown into an industry-leading supplier of high-quality custom research-grade peptides, stable isotope-labeled bioanalytical peptide standards, and custom antibodies. The company serves top-tier pharmaceutical and biotechnology companies as well as academic research institutions, having successfully synthesized tens of thousands of custom peptides while consistently meeting the highest standards of quality, service, and technical expertise.

The proceeds from this financing round will be used to support New England Peptide’s global growth strategy, including expanding its peptide synthesis capabilities to better serve the company’s growing global customer base. As part of the transaction, Dr. José de Chastonay will become the new Executive Chairman of New England Peptide’s Board of Directors.

Dr. José de Chastonay holds a Ph.D. in Medical Microbiology from the University of Bern and an MBA from Europa-Universität Viadrina. He is a seasoned executive with over 30 years of industry experience, having held senior leadership and consulting roles at various organizations specializing in the manufacturing of active pharmaceutical ingredients (APIs) and research chemicals. His most recent position was Chief Marketing Officer and member of the Corporate Executive Committee at Bachem Holding AG. His previous roles include President and CEO of Irvine Scientific and President of Bachem Americas.

Sam Massoni, CEO and Founder of New England Peptide, stated, “The partnership between New England Peptide and Ampersand is an exciting milestone in our company’s history. With Ampersand’s support, New England Peptide is better positioned to compete in the market, enhancing our standing in the custom peptide synthesis sector while maintaining our existing growth trajectory. We are also delighted to collaborate with José de Chastonay, whose valuable insights will contribute to our evolving growth strategy.”

Eric Lev, a partner at Ampersand, added, “New England Peptide is an excellent fit for Ampersand’s growth investment strategy, having already established a leadership position in its specialized market segment. We are excited about the opportunity to collaborate with Sam, Jennifer, and the entire New England Peptide team.”

Dr. José de Chastonay stated, “I see significant opportunities to leverage New England Peptide’s reputation for quality to sustain the company’s rapid growth in the coming years. I am delighted to have the opportunity to collaborate with the management team at New England Peptide to drive the company’s future success.”

Ampersand Capital Partners, established in 1988 with offices in Massachusetts, USA, and Amsterdam, the Netherlands, is a end-market private equity firm dedicated to growth investments in the healthcare sector.

(Compiled by: He Li)